Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu1
暂无分享,去创建一个
Markus Klinger | Angelika B. Riemer | Stefan Wagner | H. Pehamberger | L. Mazzucchelli | A. Riemer | S. Wagner | C. Zielinski | O. Scheiner | Luca Mazzucchelli | Hubert Pehamberger | E. Jensen‐Jarolim | Erika Jensen-Jarolim | Otto Scheiner | Christoph C. Zielinski | Astrid Bernhaus | M. Klinger | Astrid Bernhaus
[1] Hsiao‐Bai Yang,et al. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma , 1997, Virchows Archiv.
[2] V. Sexl,et al. MAP Kinase Stimulation by cAMP Does Not Require RAP1 but SRC Family Kinases* , 2002, The Journal of Biological Chemistry.
[3] F. Wouters,et al. Fluorescence lifetime imaging of receptor tyrosine kinase activity in cells , 1999, Current Biology.
[4] M. Cheever,et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Breiteneder,et al. Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] Y. Yarden,et al. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. , 1998, Biochimica et biophysica acta.
[8] I. Pastan,et al. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. , 1993, Gene.
[9] G. P. Smith,et al. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. , 1988, Gene.
[10] Y. Yarden,et al. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. , 2000, Immunology Letters.
[11] P. Triozzi,et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.
[12] J. O’Shaughnessy,et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. , 2002, Clinical breast cancer.
[13] R. Weinberg,et al. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity , 1986, Molecular and cellular biology.
[14] S J Rodda,et al. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. , 1986, Molecular immunology.
[15] T. Fleming,et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .
[16] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Ward,et al. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines , 2001, Cancer Immunology, Immunotherapy.
[18] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[19] M. Cheever,et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[21] L. Mazzucchelli,et al. Cell-specific peptide binding by human neutrophils. , 1999, Blood.
[22] J. Murray,et al. Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. , 1997, Anticancer research.
[23] Yosef Yarden,et al. Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.
[24] C. Cordon-Cardo,et al. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.
[25] S. Ménard,et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Provinciali,et al. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA , 1997, Cancer Immunology, Immunotherapy.
[27] M. Greene,et al. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.
[28] N. Hynes,et al. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. , 1993, British Journal of Cancer.
[29] Y. Yarden,et al. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Gralow,et al. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. , 1996, Journal of immunology.
[31] H. Pehamberger,et al. Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library. , 2002, The Journal of investigative dermatology.
[32] A. M. Stanley,et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.
[33] C. Barbas,et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[34] N. Lemoine,et al. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.
[35] S. Ménard,et al. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.
[36] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[39] E. Kuechler,et al. Uncoating of human rhinovirus serotype 2 from late endosomes , 1994, Journal of virology.
[40] N. Hynes,et al. The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.
[41] J. Koch,et al. Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design1 , 2001, The Journal of Immunology.
[42] L. Harris,et al. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. , 2001, European journal of cancer.
[43] A Sette,et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.
[44] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[45] Wei Chen,et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.
[46] H. Rammensee,et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.
[47] A. Folgori,et al. Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. , 1993, Gene.
[48] L. Esserman,et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.
[49] J. Manola,et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.